1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2009
          2009
          12 October 2009
          : 5
          : 781-787
          Affiliations
          [1 ] Thoracic-Oncology Unit 1st, Lung Diseases Department, San Camillo-Forlanini High Specialization Hospitals, Rome, Italy;
          [2 ] Sperimental Medicine Department, Rome, Italy
          Author notes
          Correspondence: Serena Ricciardi, Thoracic Oncology Unit 1st, Lung Diseases Department, San Camillo-Forlanini High Specialization, Hospitals, Rome, Italy, Email sricciardi@ 123456interfree.it
          Article
          tcrm-5-781
          2762436
          19851525
          © 2009 Ricciardi et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Medicine

          pemetrexed, non-squamous carcinoma, first-line setting, non-small cell lung cancer

          Comments

          Comment on this article